Intramuscular myxomas are a rare benign type of soft tissue myxoma that is mesenchymal in origin.
Incidence is reported to be 1 in 1 000 000 and most frequently diagnosed in females (~57%) patients between 40-70 years 1.
The typical presentation is that of a slowly enlarging mass(es) in 64% of patients 1. The lesions are a deeply seated mass confined to skeletal muscle and without malignant potential. A painful mass will be present in ~55% of patients 1,3.
Myxomas have been reported to range in size from 1-17 cm 1,2. Intramuscular myxomas can be solitary or multiple, when multiple myxomas are present they are associated with monostotic or polyostotic fibrous dysplasia, known as Mazabraud syndrome 1,3-5.
Intramuscular myxomas can be located in any skeletal muscle group however most commonly occur in the quadriceps (65%), hip adductors (~35%), gluteus muscles (~20%), gastrocnemius and upper arm 1,3. When occurring in conjunction with fibrous dysplasia they are typically located in the vicinity of the bone lesions. Both fibrous dysplasia and intramuscular myxomas most commonly affect the pelvic girdle and lower limbs (75%). The upper limbs are affected in less than a quarter of reported cases.
- lesions are generally hypocellular and hypovascular although areas of increased vascularity and cellularity may be present 1
- there is loose reticulin fibers within an abundant myxoid stroma1,6
- the cells have a stellate shape with small hyperchromatic pyknotic nuclei and scanty cytoplasm
- there is the absence of nuclear atypia, mitotic figures or necrosis 6
There may be a link with postzygotic mutations of the GNAS1 gene located on chromosome 20q13.2 – q13.3, particularly when associated with Mazabraud syndrome 3-5. GNAS1 encodes the alpha sub-unit of G-protein (GSa) involved in cell proliferation 3-5. This mutation affects the mesenchymal precursor cells at the early stages of commitment 5.
- fibrous dysplasia as part of Mazabraud syndrome
- McCune –Albright syndrome: cafè-au-lait skin pigmentations and endocrine dysfunction, such as precocious puberty, diabetes mellitus, goiter and breast fibroadenomatosis 7
Typically seen as a well-circumscribed intramuscular mass. Some may have partially ill-defined borders.
Most commonly demonstrate normal findings (~ 55%) or a non-specific soft-tissue mass (45%) 1.
Demonstration of a well-defined hypoechoic to near anechoic mass to the surrounding soft tissue and often shows a heterogeneous echotexture 1. Posterior acoustic enhancement may be observed in a significant portion of cases. There may be some internal echoes and increased through transmission 1.
In ~85% of cases, there is a sonographic bright rim sign of increased echogenicity around the myxoma (i.e. peripheral rim of echogenicity) 1. Frequently noted is the bright cap sign seen as a triangular hyperechoic area adjacent to at least one of the poles of the mass 1. The lesion is hypovascular or avascular on color Doppler US.
Intramuscular myxomas appear as well-demarcated, homogenous and hypodense ovoid lesions. The soft tissue mass attenuation is higher than that of water and less than that of surrounding tissue 1. They usually show mild diffuse enhancement or peripheral and septal enhancement seen in approximately 50% of cases 1.
MRI features include:
- intra-tumoral cysts may be present in a small proportion of cases
- pseudocapsule, perilesional/rim of fat and perilesional edema may be present
- T1: hypointense to muscle
- T2: hyperintense
T1 C+: four different patterns have been described
- peripheral enhancement
- peripheral and patchy internal enhancement
- peripheral and linear internal enhancement
- heterogeneous internal enhancement 10
Intramuscular myxomas may show 18-FDG avidity on PET/CT 4,9.
Treatment and prognosis
As the myxomas are benign, conservative treatment is recommended 10. Myxomas should be excised if they cause pain, pressure symptoms, neurological symptoms or interfere with functionality.
A recent case study described the use of bisphosphonate therapy providing a clear reduction in the diameter of intramuscular myxoma after the use of zoledronic acid for 4 years 5.
Histopathological investigation should be performed when there is an uncertainty of diagnosis to exclude other differentials including primary malignancy or metastatic disease 10.
The most common complication of myxomatous surgical excision is recurrence which occurs in ~ 30% of cases at a median of 8.5 years (range: 1.9-16 years) 3. Highly cellular lesions have higher recurrence rates however size, increased number and younger age at diagnosis are not significantly associated with recurrence 3.
- peripheral nerve sheath tumors
- chronic intramuscular hematoma
- myxoid liposarcoma
- myxoid malignant fibrous histiocytoma
- extraskeletal myxoid chondrosarcoma
- botryoid rhabdomyosarcoma 10
- 1. Jonelle M. Petscavage-Thomas, Eric A. Walker, Chika I. Logie, Loren E. Clarke, Dennis M. Duryea, Mark D. Murphey. Soft-Tissue Myxomatous Lesions: Review of Salient Imaging Features with Pathologic Comparison. (2014) RadioGraphics. 34 (4): 964-80. doi:10.1148/rg.344130110 - Pubmed
- 2. Murphey MD, McRae GA, Fanburg-Smith JC, Temple HT, Levine AM, Aboulafia AJ. Imaging of soft-tissue myxoma with emphasis on CT and MR and comparison of radiologic and pathologic findings. (2002) Radiology. 225 (1): 215-24. doi:10.1148/radiol.2251011627 - Pubmed
- 3. Majoor BCJ, van de Sande MAJ, Appelman-Dijkstra NM, Leithner A, Jutte PC, Vélez R, Perlaky T, Staals EL, Bovée JVMG, Hamdy NAT, Dijkstra SPD. Prevalence and Clinical Features of Mazabraud Syndrome: A Multicenter European Study. (2019) The Journal of bone and joint surgery. American volume. 101 (2): 160-168. doi:10.2106/JBJS.18.00062 - Pubmed
- 4. Kushchayeva YS, Kushchayev SV, Glushko TY, Tella SH, Teytelboym OM, Collins MT, Boyce AM. Fibrous dysplasia for radiologists: beyond ground glass bone matrix. (2018) Insights into imaging. 9 (6): 1035-1056. doi:10.1007/s13244-018-0666-6 - Pubmed
- 5. Vescini F, Falchetti A, Tonelli V, Carpentieri M, Cipri C, Cosso R, Kara E, Triggiani V, Grimaldi F. Mazabraud's Syndrome: A Case Report And Up-To-Date Literature Review. (2018) Endocrine, metabolic & immune disorders drug targets. doi:10.2174/1871530319666181226103700 - Pubmed
- 6. Kabukcuoglu F, Kabukcuoglu Y, Yilmaz B, Erdem Y, Evren I. Mazabraud's syndrome: intramuscular myxoma associated with fibrous dysplasia. (2004) Pathology oncology research : POR. 10 (2): 121-3. doi:PAOR.2004.10.2.0121 - Pubmed
- 7. Biazzo A, Di Bernardo A, Parafioriti A, Confalonieri N. Mazabraud syndrome associated with McCune-Albright syndrome: a case report and review of the literature. (2017) Acta bio-medica : Atenei Parmensis. 88 (2): 198-200. doi:10.23750/abm.v88i2.5256 - Pubmed
- 8. Wu JS, Hochman MG. Soft-tissue tumors and tumorlike lesions: a systematic imaging approach. Radiology. 2009;253 (2): 297-316. Radiology (full text) - doi:10.1148/radiol.2532081199 - Pubmed citation
- 9. Nishio J, Naito M. FDG PET/CT and MR imaging of intramuscular myxoma in the gluteus maximus. World J Surg Oncol. 2012;10 (1): 132. doi:10.1186/1477-7819-10-132 - Free text at pubmed - Pubmed citation
- 10. Munksgaard PS, Salkus G, Iyer VV, Fisker RV. Mazabraud's syndrome: case report and literature review. (2013) Acta radiologica short reports. 2 (4): 2047981613492532. doi:10.1177/2047981613492532 - Pubmed